SS Innovations International (NASDAQ: SSII) is steadily advancing its position in the surgical robotics sector, leveraging robust adoption in India to fuel international expansion. The company’s SSi Mantra system recently achieved a notable milestone when more than 50 robotic procedures were performed in a single day at Mohak Bariatrics and Robotics in Indore, India. This feat underscores the system’s reliability and efficiency, which are critical factors for hospitals evaluating robotic platforms.
According to the company, 224 SSi Mantra systems have been installed across 12 countries, and robotic procedures surged 143% year-over-year during the second quarter of 2026. Quarterly revenue climbed 39% to $13.9 million, with system sales rising 41% to $12.4 million, while 30 new systems were installed during the quarter. These figures highlight accelerating adoption and growing utilization of the platform, which is designed to make robotic surgery more affordable and accessible.
India remains SS Innovations’ primary commercial market, but the company is aggressively pursuing regulatory approvals in Europe and the United States. CE marking is targeted for the end of 2026, and FDA review of its 510(k) application is now expected by the end of the first quarter of 2027. These regulatory milestones are pivotal because they would open the door to two of the world’s largest healthcare markets, where demand for cost-effective surgical robotics is high. The company is also developing telesurgery capabilities and expanding surgeon training programs, which could further drive utilization and adoption in new regions.
The broader implications of SS Innovations’ progress extend beyond its own financial performance. The surgical robotics market has historically been dominated by expensive systems that limit access for many hospitals, particularly in emerging economies. By offering a more affordable alternative, SS Innovations could disrupt the status quo and expand the overall market. The company’s focus on cardiac surgery and its comprehensive suite of SSi Mudra instruments also positions it to address complex procedures that require precision and flexibility.
As the company continues to scale, its ability to execute on regulatory timelines and ramp up installations outside India will be closely watched. For investors, the latest operational and financial metrics provide tangible evidence of traction. The news is being distributed through TechMediaWire, a specialized communications platform that is part of the Dynamic Brand Portfolio at IBN. TechMediaWire offers access to a vast network of wire solutions via InvestorWire, along with editorial syndication to 5,000+ outlets and social media distribution to millions of followers. The platform also provides corporate communications solutions tailored to public and private companies.
For those seeking more details, the full article is available at https://ibn.fm/6FPBS, and additional information on SS Innovations can be found at SS Innovations International (NASDAQ: SSII). As the company navigates regulatory pathways and expands its global footprint, its performance will serve as a bellwether for the acceptance of cost-effective robotic surgery solutions worldwide.
